Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Open, Age-stratified Study to Assess Immunogenicity and Safety of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to 3-dose Schedule (0,1,6 Months) in Healthy Female Subjects Aged 15 - 55 Years and Long Term Follow-up

NCT00196937 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00196937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00196937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Open, Age-stratified Study to Assess Immunogenicity and Safety of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to 3-dose Schedule (0,1,6 Months) in Healthy Female Subjects Aged 15 - 55 Years and Long Term Follow-up
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
October 7, 2004
Completion date
December 15, 2005
Enrollment
667 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

infections, papillomavirus